Here is the kind of money OPK can get!!
Under the terms of OPKO’s agreement with TESARO (TSRO
Loading...
Loading...
), OPKO is eligible to receive payments of up to $121 million, including up-front and additional payments based on regulatory and commercialization milestones, including acceptance by FDA of the NDA. OPKO will receive double digit tiered-royalties on sales of rolapitant. In addition, TESARO (TSRO
Loading...
Loading...
) and OPKO will share future profits from the commercialization of rolapitant in Japan, and OPKO will have an option to market the products in Latin America.